Note 11 - Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Quarterly Financial Information [Table Text Block]

	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012
Revenues	$	931,397		$	258,237		$	219,575		$	2,161,501
Loss from Operations		(7,481,875	)		(9,161,724	)		(7,841,541	)		(5,561,466	)
Net Income (Loss)		(6,398,894	)		(5,906,870	)		(12,315,676	)		2,206,800
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(5,387,146	)		(5,078,684	)		(10,877,836	)		3,109,524
Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.15	)	$	(0.14	)	$	(0.30	)	$	0.07
Weighted Average Shares Outstanding, Basic		35,657,563			35,745,675			35,879,245			42,236,226
Weighted Average Shares Outstanding, Diluted		35,657,563			35,745,675			35,879,245			42,565,945

	March 31, 2011			June 30, 2011			September 30, 2011			December 31, 2011
Revenues	$	2,473,982		$	569,049		$	3,801,267		$	1,945,911
Loss from Operations		(5,112,153	)		(6,627,596	)		(6,961,324	)		(6,404,098	)
Net Income (Loss)		(5,745,366	)		11,130,148			(2,878,554	)		(7,735,953	)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.		(5,499,059	)		11,368,224			(2,691,341	)		(7,191,494	)
Basic Earnings (Loss) Per Share Available for Common Shareholders	$	(0.19	)	$	0.38		$	(0.08	)	$	(0.20	)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$	(0.19	)	$	0.30		$	(0.08	)	$	(0.20	)
Weighted Average Shares Outstanding, Basic		29,110,979			30,033,049			35,447,032			35,553,413
Weighted Average Shares Outstanding, Diluted		29,110,979			37,588,006			35,447,032			35,553,413